<DOC>
	<DOCNO>NCT02694718</DOCNO>
	<brief_summary>The purpose study determine pathological complete tumor response rate .</brief_summary>
	<brief_title>A Study Capecitabine Plus Oxaliplatin Combination With Pre-operative Pelvic Radiotherapy Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically confirm locally advanced T3/T4 rectal carcinoma without nodal involvement require surgery primary tumor Eastern Cooperative Oncology Group performance status 02 Adequate value laboratory parameter Evidence distant metastasis Previous Chemotherapy immunotherapy colorectal cancer Previous radiotherapy pelvis Preexisting condition would deter radiotherapy Malignancy within last 5 year , except cure basal cell cancer skin situ cancer cervix Clinically significant cardiac disease myocardial infarction within last 12 month Lack physical integrity upper gastrointestinal tract malabsorption syndrome Organ allograft Concomitant treatment brivudine , lamivudine , ribavirin nucleoside analogue Dihydropyrimidine dehydrogenase ( DPD ) deficiency History uncontrolled seizure , central nervous system disorder , psychiatric disability judge investigator clinically significant , preclude informed consent interfere compliance oral drug intake</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>